A Jay Freeman1, Meghana Sathe2, Enid Aliaj3, Drucy Borowitz4, Barbra Fogarty5, Christopher H Goss6, Steven Freedman7, Sonya L Heltshe8, Umer Khan5, Dara Riva3, Christina Roman3, Melita Romasco5, Sarah Jane Schwarzenberg9, Carmen A Ufret-Vincenty3, Baha Moshiree10. 1. Division of Gastroenterology, Hepatology and Nutrition, Children's Healthcare of Atlanta, Emory University, Atlanta, GA, USA. Electronic address: afreem6@emory.edu. 2. Division of Gastroenterology, Hepatology and Nutrition, Children's Health University of Texas Southwestern, Dallas, TX, USA. 3. Cystic Fibrosis Foundation, Bethesda, MD, USA. 4. Cystic Fibrosis Foundation, Bethesda, MD, USA; Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA. 5. Seattle Children's Hospital Research Institute, Seattle, WA, USA. 6. Seattle Children's Hospital Research Institute, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA. 7. Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 8. Seattle Children's Hospital Research Institute, Seattle, WA, USA; Department of Pediatrics, University of Washington, Seattle, WA, USA. 9. University of Minnesota Masonic Children's Hospital, Minneapolis, MN, USA. 10. University of North Carolina, Atrium Health, Charlotte, NC, USA.
Abstract
BACKGROUND: Gastrointestinal (GI) involvement among persons with cystic fibrosis (CF) is highly prevalent, representing a significant source of morbidity. Persons with CF have identified GI concerns as a top research priority, yet universal clinical outcome measures capturing many of the GI symptoms experienced in CF are lacking. The GALAXY study was envisioned to address this unmet need. METHODS: The GALAXY study team partnered with Community Voice, a community of patients with CF and their caregivers, to identify the patient reported outcome measures that most accurately reflected their experience with GI symptoms in CF. We also surveyed CF care teams to identify the comfort level of various team members (providers, nurses and dieticians) in managing a variety of GI conditions. RESULTS: Members of Community Voice identified the combination of PAC-SYM, PAGI-SYM, PAC-QOL and the Bristol Stool scale with three additional symptom-specific questions as patient-reported outcome measures that comprehensively captured the CF experience with GI disease. CF care team providers reported a high level of comfort in treating GI conditions including constipation (92%), GERD (93%), and gassiness (77%), however comfort level was limited to only first-line interventions. CONCLUSION: By partnering with persons with CF as well as their caregivers and medical providers, the GALAXY study is designed to uniquely capture the prevalence and severity of GI involvement among persons with CF in a manner that reflects the CF patient experience. The results of GALAXY will inform the development of future interventional trials and serve as a reproducible and objective study endpoint.
BACKGROUND: Gastrointestinal (GI) involvement among persons with cystic fibrosis (CF) is highly prevalent, representing a significant source of morbidity. Persons with CF have identified GI concerns as a top research priority, yet universal clinical outcome measures capturing many of the GI symptoms experienced in CF are lacking. The GALAXY study was envisioned to address this unmet need. METHODS: The GALAXY study team partnered with Community Voice, a community of patients with CF and their caregivers, to identify the patient reported outcome measures that most accurately reflected their experience with GI symptoms in CF. We also surveyed CF care teams to identify the comfort level of various team members (providers, nurses and dieticians) in managing a variety of GI conditions. RESULTS: Members of Community Voice identified the combination of PAC-SYM, PAGI-SYM, PAC-QOL and the Bristol Stool scale with three additional symptom-specific questions as patient-reported outcome measures that comprehensively captured the CF experience with GI disease. CF care team providers reported a high level of comfort in treating GI conditions including constipation (92%), GERD (93%), and gassiness (77%), however comfort level was limited to only first-line interventions. CONCLUSION: By partnering with persons with CF as well as their caregivers and medical providers, the GALAXY study is designed to uniquely capture the prevalence and severity of GI involvement among persons with CF in a manner that reflects the CF patient experience. The results of GALAXY will inform the development of future interventional trials and serve as a reproducible and objective study endpoint.
Authors: Christine de la Loge; Elyse Trudeau; Patrick Marquis; Peter Kahrilas; Vincenzo Stanghellini; Nicholas J Talley; Jan Tack; Dennis A Revicki; Anne M Rentz; Dominique Dubois Journal: Qual Life Res Date: 2004-12 Impact factor: 4.147
Authors: H P J van der Doef; F T M Kokke; F J A Beek; J W Woestenenk; S P Froeling; R H J Houwen Journal: J Cyst Fibros Date: 2009-12-08 Impact factor: 5.482
Authors: Jeffrey S Hyams; Carlo Di Lorenzo; Miguel Saps; Robert J Shulman; Annamaria Staiano; Miranda van Tilburg Journal: Gastroenterology Date: 2016-02-15 Impact factor: 22.682
Authors: M Boon; J Calvo-Lerma; I Claes; T Havermans; I Asseiceira; A Bulfamante; M Garriga; E Masip; B A M van Schijndel; V Fornes; C Barreto; C Colombo; P Crespo; S Vicente; H Janssens; J Hulst; P Witters; R Nobili; L Pereira; M Ruperto; E Van der Wiel; J G Mainz; K De Boeck; C Ribes-Koninckx Journal: J Cyst Fibros Date: 2020-04-22 Impact factor: 5.482
Authors: Nicola J Rowbotham; Sherie Smith; Paul A Leighton; Oli C Rayner; Katie Gathercole; Zoe C Elliott; Edward F Nash; Tracey Daniels; Alistair J A Duff; Sarah Collins; Suja Chandran; Ursula Peaple; Matthew N Hurley; Keith Brownlee; Alan R Smyth Journal: Thorax Date: 2017-08-04 Impact factor: 9.139
Authors: Mieke Boon; Ine Claes; Trudy Havermans; Victoria Fornés-Ferrer; Joaquim Calvo-Lerma; Inês Asseiceira; Anna Bulfamante; María Garriga; Etna Masip; Sandra Woodcock; Sylvia Walet; Celeste Barreto; Carla Colombo; Paula Crespo; Els Van der Wiel; Jessie Hulst; Sandra Martinez-Barona; Rita Nobili; Luisa Pereira; Mar Ruperto; Saioa Vicente; Kris De Boeck; Carmen Ribes-Koninckx Journal: PLoS One Date: 2019-12-20 Impact factor: 3.240
Authors: Meghana Sathe; Baha Moshiree; Phuong T Vu; Umer Khan; Sonya L Heltshe; Melita Romasco; Steven D Freedman; Sarah Jane Schwarzenberg; Christopher H Goss; A Jay Freeman Journal: J Cyst Fibros Date: 2021-07-22 Impact factor: 5.527